News Zentalis Pharmaceuticals, Inc.

Equities

ZNTL

US98943L1070

Market Closed - Nasdaq Other stock markets 01:30:00 16/05/2024 am IST			5-day change	1st Jan Change
11.98 ^USD	+2.61%		-3.66%	-20.96%

08/05	Stifel Adjusts Price Target on Zentalis Pharmaceuticals to $32 From $36, Maintains Buy Rating	MT
07/05	Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit	14/05	AQ
Stifel Adjusts Price Target on Zentalis Pharmaceuticals to $32 From $36, Maintains Buy Rating	08/05	MT
Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress	07/05	AQ
Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05	CI
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02/05	AQ
Zentalis Pharmaceuticals, Inc. Announces Executive Changes	11/04	CI
Zentalis Pharmaceuticals, Inc. Announces CFO Changes	11/04	CI
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS Inhibitors at AACR Annual Meeting 2024	03/04	AQ
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024	03/04	AQ
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating That Wee1 Inhibitor Azenosertib Exerts Synergistic Anti-Tumor Activity with Kras(G12c) Inhibitors At Aacr Annual Meeting 2024	03/04	CI
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02/04	AQ
Zentalis Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)	04/03	AQ
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02/03	AQ
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences	28/02	AQ
Wedbush Raises Zentalis Pharmaceuticals' PT to $15 From $12, Tweaks Financing Assumptions, Says Still on Track to Share Multiple Azenosertib Datasets in 2024, 2025; Keeps Neutral Rating	28/02	MT
Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02	CI
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates	27/02	AQ
Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference	13/02	AQ
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02/02	AQ
Zentalis Pharmaceuticals Names Chief Medical Officer, Chief Business Officer	25/01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Zentalis Pharmaceuticals, Inc.

Equities

ZNTL

US98943L1070

Summary

Filters